Cue Biopharma, Inc. Leadership Transition Update

Here is the latest update on Cue Biopharma, Inc. in plain English to help you understand what this means for your investment.

1. What happened?

Cue Biopharma is undergoing a major leadership change. On March 26, 2026, President and CEO Dr. Usman Azam resigned from his role and the Board of Directors. To ensure stability, the Board has appointed Lucinda Warren as Interim President and CEO. She has served as the company’s Chief Financial and Business Officer since 2023.

2. Why did it happen?

The company did not provide a specific reason for Dr. Azam’s departure in its filing. However, this move follows a period of significant financial pressure. In its last annual report, Cue Biopharma reported a $68 million loss, which forced the company to cut staff and narrow its research focus to its lead drug, CUE-101. Ms. Warren’s appointment—given her 25-year background at Johnson & Johnson—signals a strategic pivot toward tighter spending, potential asset sales, and securing partnerships to extend the company’s remaining cash.

3. Why does this matter for investors?

For a biotech company, the CEO is the primary face of the firm to investors and the main driver of fundraising. A sudden departure creates uncertainty, which often leads to short-term stock price volatility. Investors now need to determine if Ms. Warren will maintain the current research trajectory or prepare the company for a potential sale of its technology.

4. Who is affected?

• Shareholders: You face higher risk. The company’s market value has been under pressure due to the high costs of clinical trials.
• The Company: The focus is shifting from pure research to business development. With Ms. Warren’s expertise in licensing, the company will likely prioritize finding outside funding or partners to avoid "dilution"—the process of issuing more shares, which would reduce the value of your current holdings.

5. What happens next?

Ms. Warren will lead the company while the Board searches for a permanent CEO. Her immediate priority is managing the company’s cash, which is currently projected to last until late 2026. Keep a close eye on the next quarterly report for updates on cash burn rates and progress regarding the CUE-101 clinical trials.

6. Investor Checklist: What to watch

• Expect Volatility: Leadership changes often trigger automated selling and cause institutional investors to pause. Don't be surprised by price swings in the coming weeks.
• Watch for Deals: Given Ms. Warren’s background, any news regarding a partnership or licensing deal is a major event. These deals are the most likely catalyst for a significant change in the company’s valuation.
• The "Wait and See" Approach: The company is currently in a holding pattern. Until a permanent CEO is named or a major deal is signed, the stock may lack a clear catalyst for growth. Monitor the company’s cash reserves compared to its spending to gauge how soon they might need to raise more capital.